Structure Therapeutics (NASDAQ:GPCR) Receives New Coverage from Analysts at Morgan Stanley

Morgan Stanley assumed coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note issued to investors on Monday morning, Marketbeat reports. The brokerage issued an overweight rating and a $118.00 target price on the stock.

Several other research analysts also recently issued reports on GPCR. Cantor Fitzgerald reaffirmed an overweight rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research note on Monday, September 16th. JMP Securities decreased their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a research report on Friday, August 9th. Finally, BMO Capital Markets increased their target price on shares of Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research report on Friday, June 7th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of Buy and an average price target of $88.33.

Structure Therapeutics Price Performance

Structure Therapeutics stock opened at $41.53 on Monday. The business has a 50 day moving average of $37.98 and a 200-day moving average of $39.72. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $75.02. The company has a market capitalization of $1.94 billion, a P/E ratio of -54.71 and a beta of -3.52.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. Equities analysts anticipate that Structure Therapeutics will post -0.86 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Sandia Investment Management LP bought a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $39,000. Quarry LP bought a new position in shares of Structure Therapeutics in the 2nd quarter worth $79,000. Sectoral Asset Management Inc. bought a new position in shares of Structure Therapeutics in the 4th quarter worth $139,000. ADAR1 Capital Management LLC bought a new position in shares of Structure Therapeutics in the 4th quarter worth $163,000. Finally, Mather Group LLC. bought a new position in shares of Structure Therapeutics in the 2nd quarter worth $214,000. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.